(ALNY) Alnylam Pharmaceuticals, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ALNY) Alnylam Pharmaceuticals, Inc. Complete Analysis Pack
See the Bigger Picture
This Alnylam Pharmaceuticals, Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. What you see on this page is a real preview of the actual report, not just marketing text, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
AMVUTTRA 2024 ATTR-CM approval
AMVUTTRA’s ATTR-CM label expansion opens a far larger market than hATTR polyneuropathy; the global ATTR-CM market is now measured in the billions, not a niche. In 2024, AMVUTTRA generated about $1.2 billion in net product revenue, showing strong launch traction and high priority inside Alnylam Pharmaceuticals, Inc. It is the clearest Star in the portfolio.
AMVUTTRA hATTR-PN core franchise
AMVUTTRA is Alnylam Pharmaceuticals, Inc.’s original vutrisiran launch in hereditary ATTR polyneuropathy, and it sits in a rare-disease market where Alnylam already has strong specialist access and brand trust. Its once-every-3-month RNAi dosing supports adoption, especially versus less convenient regimens. With strong share and continued growth in 2025, it fits a Star in the BCG Matrix.
AMVUTTRA global rollout 2025
Alnylam kept AMVUTTRA in a strong rollout phase in 2025, with U.S. ATTR-CM approval from HELIOS-B data showing a 28% lower risk of all-cause mortality and recurrent cardiovascular events. Wider launch work in Europe, Japan, and other markets expands the treatable pool as ATTR remains widely underdiagnosed. That can keep revenue growth high as diagnosis rates improve and access broadens.
AMVUTTRA earlier-line adoption
AMVUTTRA is moving earlier in the ATTR pathway after its 2025 FDA approval for ATTR-CM, and that matters because earlier diagnosis can widen the treatable pool and extend time on therapy. In HELIOS-B, 654 patients were enrolled, showing the scale behind this launch. Longer use per patient lifts lifetime revenue, but Alnylam still has to fund heavy field work and education, which fits a Star.
- Earlier diagnosis supports longer treatment duration.
- 2025 FDA approval widened the addressable market.
- 654-patient HELIOS-B backed the launch.
- Heavy commercial spend still remains necessary.
ATTR franchise 2025 scale-up
AMVUTTRA is Alnylam Pharmaceuticals, Inc.’s main growth engine in 2025, with ATTR polyneuropathy and ATTR cardiomyopathy now giving the franchise two big demand pools. The U.S. FDA approved its cardiomyopathy use in March 2025, which broadened the label beyond neuropathy and reinforced its RNAi leadership. That scale-up pattern fits a BCG Star: high growth, strong share, and rising commercial momentum.
- Two-use franchise: neuropathy plus cardiomyopathy
- March 2025 FDA label expansion
- Alnylam’s leading RNAi position
AMVUTTRA Expands Beyond Neuropathy Into a Bigger Heart Market
AMVUTTRA is Alnylam Pharmaceuticals, Inc.’s Star: 2025 FDA approval in ATTR-CM widened its market from rare neuropathy into a much larger cardiomyopathy pool. 2024 net product revenue was about $1.2 billion, showing strong scale and demand. Its quarterly dosing and HELIOS-B data support faster uptake.
| Metric | Data |
|---|---|
| 2025 label | ATTR-CM |
| 2024 revenue | About $1.2 billion |
| HELIOS-B | 654 patients |
What is included in the product
Detailed Word Document
Alnylam’s BCG Matrix maps RNAi drugs by growth and share, showing where to invest, hold, or divest.
Editable Excel File
Alnylam Pharmaceuticals, Inc. BCG Matrix: clear, one-page view to spot portfolio pain points fast.
Reference Sources
Provides a credible source trail for Alnylam Pharmaceuticals, Inc. that helps validate key claims and supports faster, more confident decision-making.
Cash Cows
GIVLAARI 2019 AHP approval
GIVLAARI won U.S. approval in 2019 for acute hepatic porphyria, a very rare, specialist-led disease with limited new patient flow. That keeps growth modest, but the product has a durable prescriber base and steady use in a niche market. In BCG terms, it fits a cash cow: low-growth, defensible, and still monetizing a proven launch.
OXLUMO 2020 PH1 approval
OXLUMO, approved in 2020 for primary hyperoxaluria type 1, fits a Cash Cow profile because PH1 is ultra-rare, affecting roughly 1 to 3 people per million, and patients need long-term therapy. That means low churn and steady repeat use, with no need for launch-level spending to keep the franchise running. Alnylam can keep the asset productive with limited commercial lift, which supports strong cash generation.
GIVLAARI mature rare-disease sales
GIVLAARI is past launch and fits a mature cash cow: acute hepatic porphyria is a tiny market, but treated patients can stay on therapy long term, so share tends to stick. For Alnylam Pharmaceuticals, Inc., demand is about retention and refills, not fast market expansion. In a narrow rare-disease pool, steady sales matter more than new starts.
OXLUMO mature rare-disease sales
OXLUMO fits the "cash cow" box because it is already established in rare-disease care, with a broad global footprint and a focused diagnosed-patient pool that limits new growth. Its sales are steady rather than fast, and promotional spend stays contained, so it can keep high share without heavy launch costs. In Alnylam Pharmaceuticals, Inc.'s 2025 mix, that means mature, lower-growth revenue that still throws off cash.
- Global footprint already in place
- High share in diagnosed patients
- Low incremental promo burden
- Steady 2025 cash generation
Inclisiran royalty income
Alnylam Pharmaceuticals, Inc. still earns recurring royalty income from Novartis's Leqvio (inclisiran) partnership, while its own support costs stay limited. That makes the stream cash-cow-like: high-margin, low-capital income tied to a growing lipid-lowering drug with broad commercial reach.
- Recurring royalties, not heavy spend
- Leqvio growth supports future cash flow
Alnylam’s Cash Cows: Rare-Drug Revenue Funding the Pipeline
In Alnylam Pharmaceuticals, Inc., GIVLAARI and OXLUMO fit Cash Cow traits: ultra-rare markets, sticky long-term use, and low launch-style spend. Leqvio royalties from Novartis add high-margin, recurring cash flow. In 2025, this mix means mature, low-growth revenue that still funds Alnylam Pharmaceuticals, Inc.'s pipeline.
| Asset | Cash cow driver |
|---|---|
| GIVLAARI | Rare, recurring use |
| OXLUMO | Ultra-rare, steady refills |
| Leqvio royalties | High-margin income |
What You See Is What You Get
Alnylam Pharmaceuticals, Inc. Reference Sources
This preview shows the exact Alnylam Pharmaceuticals, Inc. BCG Matrix report you’ll receive after purchase. No demo content or hidden changes—just the full, polished document ready for strategic review. Once purchased, the same file is instantly available for download, use, and presentation. What you see here is exactly what you get.
Dogs
ONPATTRO 2018 legacy launch
ONPATTRO was approved in 2018 for hATTR polyneuropathy, so it is Alnylam Pharmaceuticals, Inc.’s older TTR RNAi asset. With only 2 TTR RNAi drugs in the portfolio, AMVUTTRA has taken the growth role in the same market, leaving ONPATTRO as a legacy product with limited strategic upside.
ONPATTRO no ATTR-CM label
ONPATTRO lacks the ATTR-CM label, so it cannot address the fastest-growing TTR segment while Alnylam Pharmaceuticals, Inc. pushes AMVUTTRA in that space. That leaves ONPATTRO tied to the older hATTR polyneuropathy market, which is smaller and slower. In BCG terms, low growth and a narrower addressable pool make ONPATTRO dog-like.
Patisiran lifecycle decline
Patisiran, the active ingredient in ONPATTRO, is a lifecycle-peak asset that now faces a shrinking role as Alnylam’s newer RNAi products scale. ONPATTRO needs IV dosing every 3 weeks, while AMVUTTRA offers quarterly dosing, so growth is harder and upkeep costs more than it returns. That fits a dog profile: mature, low-growth, and increasingly hard to defend.
Older alliance programs
Older alliance programs in ocular and CNS R&D stayed noncommercial, so their market share was 0% and they did not build scale economics. In Alnylam Pharmaceuticals, Inc.’s FY2025 mix, value came from marketed products, while these legacy partners remained low-return assets.
- Zero commercial launch
- Near-zero market share
- No scale economics
- Low-return BCG "dog"
Inherited pre-commercial RNAi assets
Inherited pre-commercial RNAi assets at Alnylam Pharmaceuticals, Inc. still pull R&D time but have no near-term launch cash flow, so they sit in the Dog bucket. Legacy programs from Alnylam and Dicerna, which Alnylam bought for $3.3 billion in 2021, can keep spending alive without clear differentiation or timing.
High R&D drag, low monetization
No launch timing, weak strategic pull
Cash trap risk fits Dog classification
ONPATTRO Lingers as Alnylam’s Slow-Moving Dog
ONPATTRO, approved in 2018, is Alnylam Pharmaceuticals, Inc. older TTR RNAi asset and still needs IV dosing every 3 weeks.
It lacks the ATTR-CM label, so it stays tied to the smaller hATTR polyneuropathy market while AMVUTTRA takes the faster-growth role.
Legacy ocular and CNS programs, plus Dicerna assets from the 2021 $3.3 billion deal, add R&D drag but little near-term cash, so they fit Dogs.
Question Marks
Zilebesiran phase 3 hypertension
Hypertension is a huge market: the WHO says about 1.3 billion adults live with the condition worldwide, and long-acting RNAi could win share if outcomes hold. Zilebesiran is still investigational, so its current market share is 0, but phase 3 could open a large pool of patients needing fewer doses. For now, it fits the BCG "Question Mark" box: high-growth potential, no sales yet.
Fitusiran hemophilia program
Fitusiran targets a hemophilia market worth over $10 billion, but the field is crowded with factor and non-factor therapies. The program moved late-stage to approval in 2025, yet safety, label limits, and physician adoption still cap uptake. With current share still small, the upside is real, but it fits Alnylam Pharmaceuticals, Inc. as a question mark.
Cemdisiran complement disorders
Cemdisiran sits in the Question Mark box because it is still in development and has 0% commercial share, while complement-mediated disease remains a growing field with strong demand. Its value depends on proving clear benefit versus entrenched and emerging rivals in a market where C5 and upstream complement drugs are already shaping competition. If Alnylam can show better efficacy, safety, or dosing, Cemdisiran could move from pipeline risk to a real franchise.
ALN-HBV02 chronic hepatitis B
Chronic hepatitis B is a huge market: WHO estimates 254 million people live with it, and about 1.1 million die each year. ALN-HBV02 is still investigational, so it has no market share or revenue yet. The upside is large, but the clinical and regulatory risk is also high, so this is a question mark.
- 254 million patients worldwide
- High unmet need, zero revenue today
ALN-HSD NASH
ALN-HSD sits in a huge liver market: MASLD/NAFLD affects about 30% of adults worldwide, and MASH/NASH is the high-value subset. The asset is still precommercial, so it has no revenue yet, and the key value driver is future proof in clinic, not sales today.
That makes it a classic question mark: the upside could be large if efficacy and safety land, but the clinical risk is still high. In BCG terms, it needs investment before it can move toward star status.
- Big market, no revenue
- Clinical proof still missing
- High upside, high risk
- Clear question-mark profile
Alnylam’s Big-Bet Pipeline: Huge Markets, Zero Sales Moat—Yet
Alnylam Pharmaceuticals, Inc.’s Question Marks have big upside but no sales moat yet: Zilebesiran, Cemdisiran, ALN-HBV02, and ALN-HSD are still precommercial, so their market share is 0%. Their markets are large, from hypertension and complement disease to chronic hepatitis B and MASH, but each program still needs phase 3 or approval proof before revenue can scale.
| Asset | Status | Market |
|---|---|---|
| Zilebesiran | Phase 3 | Hypertension, 1.3B |
| Cemdisiran | In dev. | Complement disease |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.